Authors


Shea Vincent

Latest:

CO2 Shortages and the Case for Permanent ULT Infrastructure

The UK‘s imminent CO2 shortage crisis is second time in less than a year that CO2 shortages have threatened critical cold chains. As the demand for COVID-19 vaccines, mRNA-based therapies and precision medicine treatments grows, organizations will have to rethink their ultra-low temperature (ULT) strategies to prevent these shortages from impacting the pharma cold chain, writes Shea Vincent.


Estelle Ricoux

Latest:

Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business Models

The era of big pharma as product-first companies must end, as services become the larger priority.


Ray Almgren, Swift Sensors

Latest:

How pharmacies can safeguard Covid-19 vaccine doses

Best practices for pharmacies in storage, monitoring and maintenance of their Covid vaccine shipments


Klinge

Latest:

Rising sea level: The transportation of pharmaceuticals by sea continues to gain momentum in the quest for greater supply chain resilience

When shipping pharmaceuticals internationally, the decision of ocean shipping versus air shipping might seem obvious if the speed of air shipping is the only factor at play when sending sensitive medical supplies and drugs. For the last several years, however, more companies have decided to embrace ocean shipping as a means of delivering their medicines. Industry experts Alan Kennedy and Allan Klinge discuss how, with more cold chain control, a lower carbon footprint and lower costs, ocean-going vessels often have clear advantages over air freight.


Daryl Todd

Latest:

Improving Cross-Industry Collaboration on Drug Discount Programs

How teamwork among safety-net healthcare providers and pharma can make the difference.


Feliza Mirasol

Latest:

Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.


Denise Myshko

Latest:

Study Highlights PBMs’ Role in Drug Prices

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.


Rob Besse, Senior Vice President, Principal, Archbow Consulting

Latest:

Fair Market Value vs. Current Market Leverage

How pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution services



Mike Hollan

Latest:

Mark Cuban’s Cost Plus Drugs Partners with Price.com

The two company’s will provide consumers with a platform where they can compare drug prices.


Kevin L. Hagan and Amy Niles, PAN Foundation

Latest:

Continued Affordability Challenges in the Offing

Will result from Medicare reforms, despite increased drug uptake.


Bradley Dunlap

Latest:

Why Pharmaceutical Products Need Sustainable Packaging

One packaging aspect—the tape—is often overlooked, but is a valuable component of the shipping process.


John Santilli, AMI

Latest:

Raising the stakes for market access support

Case study on closing the gap between new specialty drugs and specialty pharmacies


Sebastian Pistritto

Latest:

How to Maximize Pharmacy Reimbursement for Every Order and Prevent Costly Write-Offs

Questions pharmacies should ask when choosing the right proof-of-delivery solution


Vishal Singal, Beghou Consulting

Latest:

Caught Beneath the Surface: The Hidden Potential of Patient Data

Filling the gaps in the patient journey within an increasingly complex data environment.


Jason Zemcik, TrialCard

Latest:

Beyond Payment Methods

The need for supporting services in copay accumulator and best price areas


Jimin Han

Latest:

The Importance of Having the Biopharma Industry Join the Journey to Net-Zero Emissions

How setting action-based goals and cultivating partnerships will help overcome challenges associated with implementing a sustainable GHG strategy.


Pooja Goyal

Latest:

Driving CAR-Ts for Treatment in Cancer and Immunology

A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.


Alan Kalton

Latest:

Democratizing AI: Bridging the Intelligence Divide in Commercial Life Sciences

Small and emerging biopharma have been historically reserved about artificial intelligence. But, writes Alan Kalton, AI solutions have matured, been proven, and are no longer a risky investment for small to mid-size companies.


Richard Peck, Tower Cold Chain

Latest:

Realistic Net-Zero Goals for Pharma

How temperature-controlled containers can play key role in the industry's mission for carbon neutrality across the supply chain.


Justin Kozak, Founder Shield

Latest:

M&A in Pharma: Balancing Growth and Risk

What factors should be considered—and how can both parties benefit long-term?


Michael Grosberg, Model N

Latest:

What Will Change in the Pharma Industry Look Like?

Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).


John Audette

Latest:

What Health & Wellness Companies Need to Know About the New Provider/Patient Relationship

How has the provider-patient relationship transformed over the past two years, and what care are consumers craving?


Deborah Ventz-Migneco

Latest:

Pharma's Journey with Patient Family Advisory Councils

Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.


Ash Aggarwal

Latest:

Creating Value from Compliance Data

How maximizing the intelligence gained from brand engagement compliance activities can help drive pharmaceutical company commercial decisions.


Valerie Bandy, PharmD

Latest:

Streamlining for Safety: Navigating Changes and Trends in the Pharmaceutical Supply Chain Post-DSCSA

With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.


Ellen Kelsay

Latest:

Climbing Health Care Costs Result in Elevated Employer Vigilance

Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.


TrustMed

Latest:

Strategic EPCIS Implementation: Optimizing Supply Chain Management through Strategic EPCIS Implementation

This document outlines key strategies and testing protocols critical for optimizing EPCIS implementation, ensuring that pharmaceutical manufacturers can maintain compliance and operational efficiency.


Sean O’Hearen, 1st Line Partners

Latest:

Welcome to the 'Dark Side'

Introducing a new Pharma Commerce column focused on combating illicit trade and protecting product integrity—and ultimately patients.


Jyot Singh

Latest:

Pharmaceutical Cold Chain Logistics in the Age of Artificial Intelligence

Building strategy, mitigating risk, and achieving success with artificial intelligence.

© 2025 MJH Life Sciences

All rights reserved.